Roche reports 9 month group sales CHF 45.86B vs CHF 44.984B last year

In the first nine months of 2025, Roche (RHHBY) achieved sales growth of 7% to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products. Pharmaceuticals Division sales rose by 9% due to continued high growth in sales of medicines for the treatment of severe diseases; Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus were the top growth drivers. Roche CEO Thomas Schinecker: “We continue to build on our positive momentum with strong sales growth of 7% at constant exchange rates. Our momentum is further reflected in our pipeline with a number of positive clinical read-outs and a record ten potentially transformative medicines progressing into the final phase of development for diseases with significant unmet need. By the end of the decade, we expect phase III clinical results for up to 19 new medicines. Our groundbreaking next-generation sequencing technology, set to launch next year, has achieved a new record for decoding a whole human genome in under four hours. Based on our strong results, we are raising our earnings outlook for the full year.”